Dendritic cell activation by a micro particulate based system containing the influenza matrix-2 protein virus-like particle (M2e VLP)

Gomes, Kimberly Braz; Allotey-Babington, Grace Lovia; D’Sa, Sucheta; Kang, Sang‐Moo; D’Souza, Martin J.

doi:10.1016/j.ijpharm.2022.121667

Cited by 5 publications

(7 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The formulations resulted in spherical MP with high product yield (>90% w/w) and MP size ranging from 800-1600 nm. It has been reported that MP in the size range of 1 to 3 µm are easily recognized and engulfed by circulating APCs [14,41]. The charge of the antigen/adjuvant MP varied depending on the encapsulated material.…”

Section: Discussionmentioning

confidence: 99%

“…Once administered, the vaccine antigen is recognized and engulfed by the circulating APCs via phagocytosis, which is then processed and presented on the surface of these cells via the MHC Class I or MHC class II pathways [34,37,40]. The expression of the antigen-presenting molecules, MHC I/II, and their co-stimulatory molecules, CD80/40, on the surface of DCs was assessed using fluorescent markers through flow cytometry analysis described previously [36][37][38]41]. For this purpose, murine DCs were plated in a 48-well plate at 3 x 10 4 cells/well density.…”

Section: Determining the Expression Of Antigen-presenting Molecules A...mentioning

confidence: 99%

See 1 more Smart Citation

Microneedle Delivery of an Adjuvanted Microparticulate Vaccine Induces High Antibody Levels in Mice Vaccinated against Coronavirus

et al. 2022

View full text Add to dashboard Cite

This ‘proof-of-concept’ study aimed to test the microparticulate vaccine delivery system and a transdermal vaccine administration strategy using dissolving microneedles (MN). For this purpose, we formulated poly(lactic-co-glycolic) acid (PLGA) microparticles (MP) encapsulating the inactivated canine coronavirus (iCCoV), as a model antigen, along with adjuvant MP encapsulating Alhydrogel® and AddaVax. We characterized the vaccine MP for size, surface charge, morphology, and encapsulation efficiency. Further, we evaluated the in vitro immunogenicity, cytotoxicity, and antigen-presentation of vaccine/adjuvant MP in murine dendritic cells (DCs). Additionally, we tested the in vivo immunogenicity of the MP vaccine in mice through MN administration. We evaluated the serum IgG, IgA, IgG1, and IgG2a responses using an enzyme-linked immunosorbent assay. The results indicate that the particulate form of the vaccine is more immunogenic than the antigen suspension in vitro. We found the vaccine/adjuvant MP to be non-cytotoxic to DCs. The expression of antigen-presenting molecules, MHC I/II, and their costimulatory molecules, CD80/40, increased with the addition of the adjuvants. Moreover, the results suggest that the MP vaccine is cross presented by the DCs. In vivo, the adjuvanted MP vaccine induced increased antibody levels in mice following vaccination and will further be assessed for its cell-mediated responses.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Determining the Expression Of Antigen-presenting Molecules A...mentioning

confidence: 99%

Microneedle Delivery of an Adjuvanted Microparticulate Vaccine Induces High Antibody Levels in Mice Vaccinated against Coronavirus

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In one study, the M2e5x VLPs were generated using cellulose acetate phthalate dispersion technology. When these VLP were accompanied by Alhydrogel and monophosphoryl lipid A (MPL-A) adjuvants, they were capable of stimulating dendritic cells via the Th1 pathway [ 40 ]. Transdermally immunizing mice with the identical adjuvanted M2e5x VLPs elicited virus-specific antibody responses and triggered the proliferation of splenic T cells [ 41 ].…”

Section: Influenza Virusmentioning

confidence: 99%

Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?

Chu

Quan

2023

Viruses

View full text Add to dashboard Cite

With technological advancements enabling globalization, the intercontinental transmission of pathogens has become much easier. Respiratory viruses are one such group of pathogens that require constant monitoring since their outbreak leads to massive public health crises, as exemplified by the influenza virus, respiratory syncytial virus (RSV), and the recent coronavirus disease 2019 (COVID-19) outbreak caused by the SARS-CoV-2. To prevent the transmission of these highly contagious viruses, developing prophylactic tools, such as vaccines, is of considerable interest to the scientific community. Virus-like particles (VLPs) are highly sought after as vaccine platforms for their safety and immunogenicity profiles. Although several VLP-based vaccines against hepatitis B and human papillomavirus have been approved for clinical use by the United States Food and Drug Administration, VLP vaccines against the three aforementioned respiratory viruses are lacking. Here, we summarize the most recent progress in pre-clinical and clinical VLP vaccine development. We also outline various strategies that contributed to improving the efficacy of vaccines against each virus and briefly discuss the stability aspect of VLPs that makes it a highly desired vaccine platform.

show abstract

“…Nanotechnology can be used to activate and amplify T cells prior to adoptive transfer in vitro . For example, MHC and immunoglobulin dimers coupled with costimulating CD28 antibodies to NPs can be enriched and activated antigen-specific T cells by applying magnetic fields to artificial APCs . Since the particles mediate antigen-specific activation (MHC-antigenic peptide) rather than polyclonal (anti-CD3), they can be further used to enrich and amplify rare tumor-specific T cells.…”

Section: Advantages Of Bnds For Tumor Immunotherapymentioning

confidence: 99%

“…For example, MHC and immunoglobulin dimers coupled with costimulating CD28 antibodies to NPs can be enriched and activated antigen-specific T cells by applying magnetic fields to artificial APCs. 181 Since the particles mediate antigen-specific activation (MHC-antigenic peptide) rather than polyclonal (anti-CD3), they can be further used to enrich and amplify rare tumor-specific T cells. In addition, another research reported that IL15 super agonists were loaded onto the plasma membrane of adoptively transferred T cells.…”

Section: Advantages Of Bnds For Tumor Immunotherapymentioning

confidence: 99%

Advanced Generation Therapeutics: Biomimetic Nanodelivery System for Tumor Immunotherapy

Li,

Zeng,

et al. 2023

ACS Nano

View full text Add to dashboard Cite

Dendritic cell activation by a micro particulate based system containing the influenza matrix-2 protein virus-like particle (M2e VLP)

Cited by 5 publications

References 48 publications

Microneedle Delivery of an Adjuvanted Microparticulate Vaccine Induces High Antibody Levels in Mice Vaccinated against Coronavirus

Microneedle Delivery of an Adjuvanted Microparticulate Vaccine Induces High Antibody Levels in Mice Vaccinated against Coronavirus

Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?

Advanced Generation Therapeutics: Biomimetic Nanodelivery System for Tumor Immunotherapy

Contact Info

Product

Resources

About